Sanofi Acquires Dynavax for $15.50 per Share, Totaling $2.2 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 24 2025
0mins
Source: Benzinga
- Acquisition Deal: Sanofi's agreement to acquire Dynavax for $15.50 per share, totaling approximately $2.2 billion, is expected to enhance its market presence in adult immunization, potentially driving future revenue growth.
- Stock Price Reaction: Following the acquisition announcement, Dynavax shares surged 38.6% to $15.44, indicating a positive market response that may attract further investor interest in the company.
- FDA Approval Impact: Omeros Corp's stock jumped 66.8% to $14.60 after the FDA approved YARTEMLEA for treating related conditions, reflecting strong market demand and optimistic expectations for potential revenues from new drugs.
- Market Dynamics: Companies like Edgewise Therapeutics and Agios Pharmaceuticals also saw significant stock price increases due to positive clinical trial results and FDA approvals, indicating a resurgence of activity and investor confidence in the biotech sector.
Analyst Views on AGIO
Wall Street analysts forecast AGIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AGIO is 36.38 USD with a low forecast of 25.00 USD and a high forecast of 62.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 28.830
Low
25.00
Averages
36.38
High
62.00
Current: 28.830
Low
25.00
Averages
36.38
High
62.00
About AGIO
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
